Niosomes are microscopic bubble-like structures made from non-ionic surfactants that can carry drugs, nutrients, or other active ingredients to specific parts of the body. Think of them as tiny delivery vehicles, each one a sphere with a water-filled interior surrounded by a double-layered membrane built from the same class of mild, uncharged detergent molecules found in everyday products like shampoos and food emulsifiers. Because they can hold both water-soluble and oil-soluble compounds at the same time, niosomes have become a versatile platform in pharmaceutical and cosmetic research, though their journey from the lab bench to the pharmacy shelf is far from complete.
What a Niosome Actually Looks Like
A niosome is a vesicle, meaning a hollow sphere enclosed by one or more concentric membrane layers. Each layer is a bilayer: two sheets of surfactant molecules arranged tail-to-tail, with their water-loving heads facing outward toward the surrounding fluid and their oil-loving tails tucked together in the middle. The water-filled core can carry hydrophilic (water-soluble) drugs, while hydrophobic (fat-soluble) drugs nestle into the oily interior of the bilayer itself. This dual-compartment design is what makes niosomes attractive as drug carriers, since many therapeutic molecules fall into one category or the other.1PubMed Central. Advances of Non-Ionic Surfactant Vesicles (Niosomes) and Their Application in Drug Delivery
The bilayer structure consists of a polar region and a non-polar region, and the overall architecture closely resembles that of a liposome, its better-known cousin.2PubMed Central. A Comprehensive Review of Niosomes: Composition, Structure, Formation, Characterization, and Applications in Bioactive Molecule Delivery Systems Most formulations also include cholesterol, which slots between the surfactant molecules and stiffens the membrane. Without cholesterol, the bilayer tends to be leaky and unstable. The ratio of surfactant to cholesterol is one of the key variables researchers adjust to control how rigid or flexible the vesicle ends up being, which in turn affects how much drug it can hold and how quickly that drug escapes.
How They Compare to Liposomes
Liposomes came first. Discovered in the 1960s, they are built from phospholipids, the same fat molecules that make up your cell membranes. Liposomes proved the concept that artificial vesicles could deliver drugs, but they come with practical headaches: phospholipids are expensive, chemically fragile, and prone to oxidation. These drawbacks drove the development of niosomes, which swap phospholipids for non-ionic surfactants that are cheaper, more chemically stable, and easier to store.3PubMed. Liposomes and Niosomes: New trends and applications in the delivery of bioactive agents for cancer therapy
Non-ionic surfactants carry no electrical charge, which makes niosomes generally less irritating to biological tissues and gives them a longer shelf life under various storage conditions. They are also nontoxic and require lower production costs compared to liposomes.4PubMed. Niosomes: novel sustained release nonionic stable vesicular systems–an overview That said, liposomes still dominate the clinical landscape because they have decades more safety data and several approved pharmaceutical products already on the market. Niosomes are essentially the budget-friendly, shelf-stable alternative still trying to prove itself in the clinic.
How Niosomes Get Made
There is no single recipe. Several preparation techniques exist, and the choice of method directly affects the size, uniformity, and drug-loading capacity of the resulting vesicles. The oldest and most common approach is thin-film hydration: surfactant and cholesterol are dissolved in an organic solvent, the solvent is evaporated off to leave a dry film on the wall of a flask, and then warm water is added and agitated to peel the film into vesicles. It works, but the vesicles it produces tend to vary a lot in size.
Newer techniques offer more control. Microfluidics, for instance, channels the surfactant solution and an aqueous phase through tiny intersecting channels at precisely controlled flow rates. Studies have shown that microfluidic production yields niosomes that are smaller and more uniform than those from thin-film hydration, and comparable in quality to ethanol injection, another conventional method.5Chemical Engineering Research and Design. Cholesterol free niosome production by microfluidics: Comparative with other conventional methods Ball milling is an even more recent addition to the toolkit, offering precise manipulation of vesicle size and shape along with improvements in drug release and encapsulation efficiency compared to traditional methods.6PubMed Central. Niosome Preparation Techniques and Structure-An Illustrated Review
Loading Drugs Into the Vesicle
Getting a drug inside a niosome can happen passively or actively. In passive loading, the drug is simply present in the solution when the vesicles form, and some fraction of it gets trapped inside the aqueous core or partitions into the bilayer. The efficiency depends on the drug’s solubility and the formulation conditions, but for many compounds the passive approach captures only a modest percentage of the available drug.
Active (or “remote”) loading techniques can do better. One approach creates a chemical gradient across the niosome membrane, such as a difference in salt concentration or pH between the interior and exterior. Drug molecules cross the membrane to equilibrate the gradient, and once inside, they become protonated or precipitate, which prevents them from leaking back out. Research on the glaucoma drug dorzolamide demonstrated this dual mechanism: loading is driven both by the charging of drug molecules inside the vesicle and by precipitation when the internal drug concentration exceeds its solubility.7PubMed Central. Dorzolamide Loaded Niosomal Vesicles: Comparison of Passive and Remote Loading Methods The result is higher entrapment and slower release, which is usually the goal.
Delivering Drugs Through the Skin
One of the most studied applications of niosomes is transdermal delivery, getting drugs across the skin barrier without an injection. The outermost layer of skin, the stratum corneum, is a tough obstacle. Niosomes appear to overcome it through a combination of mechanisms: the surfactant molecules in their membrane act as permeation enhancers that loosen the tightly packed lipids in the stratum corneum, and the vesicles themselves can fuse directly with skin cells to deposit their cargo.8PubMed. Effect of liposomes and niosomes on skin permeation of enoxacin
This makes niosomes appealing for conditions where you want a drug to concentrate in the skin rather than spread throughout the body, such as fungal infections, inflammatory skin diseases, or localized pain. The surfactant’s permeation-enhancing effect is essentially built into the delivery system itself, rather than requiring a separate chemical additive.
Eye Drops That Actually Stay Put
Delivering drugs to the eye is notoriously difficult. Blinking, tear production, and the corneal barrier all work against you, washing away most of an eye drop within minutes. Niosomes help by adhering to the mucous layer on the eye’s surface, slowing clearance and giving the drug more time to absorb. Coating niosomes with hyaluronic acid, a naturally occurring polymer found in the eye, amplifies this effect. In rabbit studies, hyaluronic acid-coated niosomes carrying the immunosuppressant tacrolimus stayed on the eye surface significantly longer than uncoated niosomes or a plain drug suspension, and the drug concentration in the aqueous humor (the fluid inside the eye) was about 2.3 times higher than with the suspension alone.9PubMed. Hyaluronic acid-coated niosomes facilitate tacrolimus ocular delivery: Mucoadhesion, precorneal retention, aqueous humor pharmacokinetics, and transcorneal permeability
Improving Oral Drug Absorption
Taking a pill seems simple, but many drugs are poorly absorbed in the gut. They dissolve poorly, get broken down by stomach acid or digestive enzymes, or are metabolized heavily by the liver before they ever reach the bloodstream. Niosomes can shield these vulnerable drugs from the harsh gastrointestinal environment and promote absorption across the intestinal lining.10PubMed. Niosomes for oral drug delivery: factors affecting pharmacokinetics and intestinal transport mechanisms
One challenge is that niosomes themselves are not perfectly stable in gastric acid. Coating them with chitosan, a polymer derived from crustacean shells, helps. In a study on ursolic acid, a plant compound with poor natural bioavailability, chitosan-coated niosomes released only about 7% of their contents in simulated stomach fluid and around 32% in simulated intestinal fluid, meaning most of the cargo survived the stomach. The coated vesicles also showed higher absorption in the duodenum and greater accumulation in the liver compared to uncoated versions.11PubMed Central. Effect of niosome formation with chitosan coating on the stability and absorption of orally administered vesicular ursolic acid
Targeting Specific Tissues
Plain niosomes go wherever the bloodstream takes them, which is not always where you want them. Surface modification can change that. Attaching specific molecules to the outside of the niosome gives it the ability to recognize and latch onto particular cell types, much like putting an address label on a package.
Some of the most ambitious targeting work involves the brain. The blood-brain barrier blocks most drugs from entering brain tissue, which makes treating brain tumors extremely difficult. Researchers have decorated niosomes with chlorotoxin, a small peptide originally found in scorpion venom that has a high affinity for glioma cells. In one study, niosomes carrying the chemotherapy drug temozolomide and tagged with chlorotoxin achieved about a three-fold increase in drug accumulation in the brain compared to unmodified niosomes. Other work has shown that attaching two targeting molecules at once, a strategy called dual ligand targeting, improves penetration through the blood-brain barrier more than either ligand alone.12PubMed Central. Surface Modification of Lipid-Based Nanocarriers: A Potential Approach to Enhance Targeted Drug Delivery
Niosomes for Gene Delivery
Delivering genetic material like DNA, small interfering RNA (siRNA), or antisense molecules into cells is one of the hardest problems in modern medicine. These molecules are large, negatively charged, and easily degraded. Viral vectors are effective but carry safety concerns. Cationic niosomes, made with positively charged surfactant or lipid components, can bind the negatively charged genetic cargo through electrostatic attraction and ferry it across cell membranes.13PubMed Central. Cationic Niosomes as Non-Viral Vehicles for Nucleic Acids: Challenges and Opportunities in Gene Delivery
One creative application combined gene delivery with imaging. Researchers encapsulated indocyanine green, a fluorescent dye, inside niosomes made from sorbitan monooleate and a cationic lipid. The resulting system could deliver siRNA and microRNA to human stem cells with high efficiency, while simultaneously allowing researchers to track the cells using near-infrared fluorescence.14PubMed. Theranostic Niosomes for Efficient siRNA/MicroRNA Delivery and Activatable Near-Infrared Fluorescent Tracking of Stem Cells These “theranostic” systems, combining therapy and diagnostics in one package, represent a growing area of niosome research.
Smart Niosomes That Respond to Their Environment
Standard niosomes release their payload gradually and somewhat indiscriminately. The latest generation of niosomal systems is engineered to respond to specific triggers, releasing drugs only when and where they are needed. These stimuli-responsive niosomes can react to internal body signals like changes in pH (tumors and inflamed tissues are more acidic than healthy tissue), shifts in the local chemical environment, or enzyme activity at a disease site. They can also respond to external triggers applied by a clinician, including light, ultrasound, magnetic fields, or focused heating.15PubMed Central. Niosomes as Vesicular Carriers: From Formulation Strategies to Stimuli-Responsive Innovative Modulations for Targeted Drug Delivery
The practical appeal is clear: a pH-sensitive niosome loaded with a chemotherapy drug could remain sealed while circulating through healthy tissue and then open up when it reaches the acidic microenvironment of a tumor. This kind of precision could reduce side effects while increasing the drug concentration at the target site. The research is still preclinical, but the concept has driven a wave of formulation work over the past few years.
Cancer Research Applications
Cancer therapy is one of the most active areas of niosome research, and for good reason. Conventional chemotherapy drugs are toxic to both cancer cells and healthy cells, so any technology that concentrates the drug at the tumor while sparing normal tissue could be transformative. Encapsulating anticancer agents in niosomes can improve their stability, extend their circulation time, and reduce exposure to healthy organs. Research on carnosine-loaded niosomes, for example, showed enhanced stability and bioavailability of the compound, leading to improved anticancer activity compared to the free drug.16PubMed. Carnosine-Niosomal Delivery System for Targeted Cancer Therapy
Combining targeted surface ligands with stimuli-responsive release is the direction much of the oncology-focused niosome work is heading. The idea is to create a system that finds the tumor, sticks to it, and only then releases its drug payload. The challenge, as with most nanomedicine, is translating this elegant lab-scale concept into something that works reliably in the messy complexity of a human body.
Safety and Biocompatibility
Non-ionic surfactants are generally regarded as safe. Many of them, like the Span and Tween families, are already approved as food additives and pharmaceutical excipients. Laboratory testing of niosomes has confirmed that they are compatible with blood cells and nontoxic to cell membranes. In one study evaluating a niosome system made from a sulfanilamide-based surfactant, the vesicles were hemocompatible (meaning they did not damage red blood cells) and showed no toxicity to cellular membranes.17PubMed Central. Hemolytic and cellular toxicology of a sulfanilamide-based nonionic surfactant: a niosomal carrier for hydrophobic drugs
That said, “safe in cell culture” and “safe in people at therapeutic doses over months” are very different standards. The safety profile of any niosome product depends heavily on the specific surfactant, the drug being carried, the route of administration, and the dose. This is part of why clinical translation has been slow: each new formulation essentially needs its own safety evaluation.
The Shelf-Life Problem and Proniosomes
Like any suspension of tiny particles in water, niosomal dispersions can degrade over time. Vesicles may fuse together, grow larger, or leak their drug cargo. Stability studies on piroxicam-loaded niosomes found that drug leakage over three months ranged from roughly 1.5% to 6.6%, and particle size increased during storage. Refrigeration at around 5°C and converting the suspension into a freeze-dried powder both improved stability, though the optimal freeze-drying process still needs refinement.18PubMed. Stability studies on piroxicam encapsulated niosomes
A more elegant solution is to skip the liquid form entirely. Proniosomes are dry, powdery formulations where surfactant is coated onto a carrier material. They sit on a shelf as a stable powder and only form niosomes when mixed with water or applied to a moist surface like the skin. This sidesteps the physical stability issues of vesicular suspensions, including aggregation, fusion, and leakage, while making the product easier to transport and store.19Open Access Journal of Pharmaceutical Research. Novel Vesicular Drug Delivery Systems Proniosomes Proniosomes integrate non-ionic surfactants, lipids, and biodegradable carriers and can be reconstituted into niosomes upon contact with an aqueous medium, achieving controlled release and enhanced drug permeation.20PubMed Central. Next-generation composite vesicular systems: an in-depth review of proniosomes in advanced drug delivery
Where You Will Actually Find Niosomes Today
Despite decades of research and hundreds of published studies, the honest picture is that niosomes have barely made it out of the lab and into real products that people use. The biggest commercial success story is in cosmetics and personal care. Various brands sell niosome-based serums and anti-aging creams, taking advantage of the technology’s ability to deliver active ingredients deeper into the skin. Niosomes have been used as cosmetic nanocarriers since the 1970s, and the industry continues to develop new formulations for sustained and targeted delivery of active cosmetic compounds.21PubMed Central. Niosomes as Vesicular Nanocarriers in Cosmetics: Characterisation, Development and Efficacy
On the pharmaceutical side, the gap between promise and practice is wide. While preclinical studies span everything from cancer to brain delivery to oral vaccines, very few niosomal formulations have entered clinical trials. The human trials that do exist have mostly focused on topical uses, including a randomized controlled trial of niosomal zinc sulfate for warts and an interventional study of rectal dexmedetomidine in a niosomal formulation. Large randomized trials and regulatory approvals are essentially nonexistent. No specific regulatory framework exists for niosomes; instead, regulators evaluate them under the general principles of nanomedicine.22Next Nanotechnology. Niosomes in drug delivery: A comprehensive review and therapeutic perspectives
Niosomes in Food and Nutraceuticals
Pharmaceutical delivery is not the only frontier. Researchers have been exploring niosomes as carriers for bioactive compounds in food and beverages, a field that blurs the line between nutrition science and nanotechnology. Adding niosomes loaded with compounds like quercetin, vitamin D, iron, resveratrol, or catechin into food products such as juice, milk, and yogurt has been shown to improve the stability of these sensitive ingredients, boost their antioxidant capacity, and enhance their bioavailability under intestinal conditions.23Food and Humanity. Nanocarriers for foods: A review of niosomes and proniosomes in bioactive compounds
One interesting approach has been co-encapsulating pairs of antioxidants, such as gallic acid with curcumin or ascorbic acid with quercetin, inside the same niosome. Research found that these combinations produced a synergistic antioxidant effect, meaning the pair was more effective at neutralizing free radicals than either compound alone. The co-encapsulation also altered the physical properties and release behavior of the vesicles, suggesting that the interaction between cargo molecules and the niosome membrane is a design variable worth exploiting.24PubMed. Co-encapsulation of antioxidants into niosomal carriers: gastrointestinal release studies for nutraceutical applications Whether niosome-fortified foods will ever become mainstream consumer products depends on resolving regulatory questions around nanoparticles in the food supply, a conversation that is still in early stages in most countries.